Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
暂无分享,去创建一个
Yukiko Nakamura | T. Yamanaka | S. Morita | S. Oizumi | H. Kenmotsu | J. Tanizaki | T. Hida | Y. Takiguchi | K. Hotta | Takaaki Sasaki | S. Miura | K. Aokage | A. Tamiya | H. Daga | Y. Goto | Y. Okuma | Kentaro Tanaka | O. Yamaguchi | T. Kozuki | K. Ninomiya | K. Nosaki | T. Sakamoto | E. Miyauchi | M. Morise | C. Imamura | Y. Oya | H. Mizutani | Hisashi Tanaka | S. Teraoka | Y. Zenke | N. Ebi | S. Amano | Kazuo Hasegawa | Kenichi Suzuki | Kazuko Nakajima | Hitomi Nishimoto | Yukiko Nakamura
[1] A. Gemma,et al. NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. , 2020 .
[2] A. Gemma,et al. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Dutt,et al. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Ahn,et al. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Toyooka,et al. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. , 2019 .
[6] Joe Y. Chang,et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[7] J. Shih,et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[8] Ying Cheng,et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.
[9] K. Prabhash,et al. P1.01-88 PS 2 Patients with Advanced EGFR Mutant NSCLC: Subset Analysis of a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy , 2019, Journal of Thoracic Oncology.
[10] Y. Shu,et al. CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC , 2019, Annals of Oncology.
[11] C. Paweletz,et al. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.
[12] R. Rosell,et al. Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.
[13] Lisheng Xu,et al. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study. , 2019, Lung cancer.
[14] N. Reinmuth,et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.
[15] T. Yamanaka,et al. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV , 2019, International Journal of Clinical Oncology.
[16] A. Gemma,et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. , 2019, The Lancet. Oncology.
[17] M. Socinski,et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. , 2019, The Lancet. Respiratory medicine.
[18] T. Mitsudomi,et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. , 2019, Annals of Oncology.
[19] Zhongfa Zhang,et al. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. , 2018, Lung cancer.
[20] Xiangdong Zhou,et al. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] T. Yamanaka,et al. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567. , 2018 .
[22] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[23] V. Gebski,et al. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis , 2017, JAMA oncology.
[24] Thomas John,et al. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] L. Sequist,et al. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) , 2017, The Patient - Patient-Centered Outcomes Research.
[26] Ying Cheng,et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.
[27] B. Han,et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] M. Ahn,et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.
[29] Yi-long Wu,et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations , 2017, British Journal of Cancer.
[30] S. Digumarthy,et al. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.
[31] M. Fukuoka,et al. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients , 2016, Japanese journal of clinical oncology.
[32] K. O'Byrne,et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. , 2016, The Lancet. Oncology.
[33] Y. Wu,et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] B. Han,et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] L. Sequist,et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. , 2015, The Lancet. Oncology.
[36] L. Sequist,et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.
[37] Koichi Goto,et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. , 2014, The Lancet. Oncology.
[38] S. Liu,et al. 1273POVERALL SURVIVAL ANALYSES OF FIRST-LINE ERLOTINIB VERSUS CHEMOTHERAPY IN THE EURTAC STUDY POPULATION CONTROLLING FOR THE USE OF POST-STUDY THERAPY. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] P Baas,et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] Yi-long Wu,et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[41] J-L Pretet,et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] Chun-Ming Tsai,et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] A. Gemma,et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] S. Kudoh,et al. First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[45] A. Gemma,et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. , 2012, The oncologist.
[46] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[47] S. Kobayashi,et al. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. , 2012, The Lancet. Oncology.
[48] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[49] J. Shih,et al. Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer , 2011, Clinical Cancer Research.
[50] A. Gemma,et al. F1000 highlights , 2010 .
[51] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[52] Mariano Provencio,et al. Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.
[53] A. Gemma,et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] G. Guyatt,et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive , 2008, BMJ : British Medical Journal.
[55] H. Kato,et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. , 2008, American journal of respiratory and critical care medicine.
[56] M. Fukuoka,et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.